- Condition: Alcohol Consumption
Interventions: Behavioral: Brief Alcohol Intervention; Other: Lifestyle brochures
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified May 2012 - Condition: Cystic Fibrosis
Interventions: Drug: Inhaled Vancomycin; Drug: Placebo (Sterile Water); Drug: Rifampin; Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX); Drug: Doxycycline; Drug: Mupirocin Nasal Ointment; Drug: 4% chlorhexidine gluconate liquid skin cleanser
Sponsors: Johns Hopkins University; Michael Boyle; Case Western Reserve University; Cystic Fibrosis Foundation
Not yet recruiting - verified May 2012 - Condition: Myopia
Interventions: Device: Hydrogen peroxide-based cleaning and disinfecting system (CLEAR CARE®/AOSEPT Plus); Device: Polyaminopropyl biguanide (PHMB) multipurpose system (ReNu MultiPlus®); Device: etafilcon A contact lens (ACUVUE® 2™); Device: lotrafilcon B contact lens (AIR OPTIX® AQUA)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified May 2012 - Conditions: Active Ethanol and Active Iomazenil; Active Ethanol and Placebo Iomazenil; Placebo Ethanol and Placebo Iomazenil; Placebo Ethanol and Active Iomazenil
Interventions: Drug: Ethanol; Drug: Iomazenil
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified April 2012 - Condition: Tinea Pedis
Interventions: Drug: Butenafine HCl Cream, 1%; Drug: Lotrimin Ultra®; Drug: Butenafine Vehicle
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Recruiting - verified April 2012 - Condition: Healthy
Interventions: Drug: 600 mg ceftaroline fosamil in 50 ml infusion volume; Drug: Placebo in 50 ml infusion volume; Drug: 600 ceftaroline fosamil in 250 ml infusion volume; Drug: Placebo in 250 ml infusion volume; Drug: 600 mg ceftaroline in 100 ml infusion volume; Drug: Placebo in 100 ml infusion volume
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012 - Condition: Cigarette Smoking
Interventions: Drug: Nicotine replacement therapy - transdermal nicotine patch; Behavioral: Tailored behavioral intervention; Behavioral: Tobacco quitline referral; Drug: Nicotine replacement therapy - nicotine gum; Drug: Nicotine replacement therapy - nicotine lozenge; Drug: Bupropion SR; Drug: Varenicline; Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum; Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge; Drug: Combination pharmacotherapy - transdermal nicotine patch + bupropion; Behavioral: Alcohol use risk reduction; Behavioral: Behavioral activation for the treatment of depression; Behavioral: Behavioral management of post-cessation weight gain
Sponsors: University of Iowa; University of Iowa; Department of Veterans Affairs
Not yet recruiting - verified May 2012 - Condition: Chronic Periodontitis
Interventions: Drug: Amoxicillin-Metronidazole combination plus oral rinse; Device: scaling and root planing
Sponsors: Georgia Health Sciences University; Georgia Health Sciences University; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified April 2012 - Conditions: Alcohol Abuse; Schizophrenia; Bipolar Disorder; Major Depressive Disorder
Intervention: Behavioral: Contingency Management
Sponsors: University of Washington; University of Washington
Not yet recruiting - verified March 2012 - Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic BlepharitisCondition: Blepharitis
Interventions: Drug: povidone iodine; Drug: Povidone-Iodine; Drug: Azithromycin; Drug: tobramycin-dexmethasone
Sponsors: Southern California Institute for Research and Education; Southern California Institute for Research and Education
Recruiting - verified March 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Oxaliplatin; Drug: Irinotecan; Drug: 5-FU; Drug: Gemcitabine; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified March 2012 - Condition: Cutaneous Abscess
Interventions: Drug: Chlorhexidine gluconate; Drug: Mupirocin
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified March 2012 - Condition: Congestive Heart Failure
Intervention: Drug: 123 iodine metaiodobenzylguanidine
Sponsors: Mayo Clinic; Mayo Clinic; GE Healthcare
Not yet recruiting - verified January 2012 - Condition: Triclosan Effects on Microbial Flora.
Intervention: Other: triclosan/triclocarban-containing personal care products
Sponsors: Stanford University; Stanford University
Recruiting - verified January 2012 - Condition: Anterior Uveitis
Interventions: Drug: 40 mg/mL Dexamethasone phosphate ophthalmic solution; Drug: Prednisolone Acetate (1%) Eyedrops; Drug: 100 mM sodium citrate buffer solution; Drug: Placebo Eyedrops
Sponsors: Eyegate Pharmaceuticals, Inc.; Eyegate Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Brain Cancer; Brain Stem Glioma
Intervention: Radiation: Radioactive iodine-labeled monoclonal antibody 8H9
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University; Johns Hopkins University School of Medicine (Data analysis only)
Recruiting - verified March 2012 - Conditions: Magnetic Resonance Spectroscopy; Ethanol; Spectroscopy
Intervention: Drug: Alcohol
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified November 2011 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Drug-Eluting Beads with Doxorubicin; Drug: Lipiodol ethanol mixture
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Condition: Central Line-Associated Bloodstream Infection
Interventions: Drug: ethanol; Drug: heparin-saline placebo
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012 - Condition: Mucinous Pancreatic Cysts
Interventions: Drug: Ethanol; Drug: Normal Saline; Drug: Chemotherapy
Sponsors: Milton S. Hershey Medical Center; Milton S. Hershey Medical Center
Recruiting - verified November 2011 - Conditions: Squamous Cell Carcinoma; Neoplasia; Head and Neck Cancer
Interventions: Drug: Proflavine; Device: High Resolution Microendoscope; Device: Identafi 3000
Sponsors: Mount Sinai School of Medicine; Sharmila Anandasabapathy; Mount Sinai School of Medicine; William Marsh Rice University
Recruiting - verified December 2011 - Conditions: Post-operative Pneumonia; Lung Cancer; Esophageal Cancer
Intervention: Procedure: Intensive Brushing Regimen
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Condition: Surgical Site Infections
Interventions: Drug: Iodine-alcohol; Drug: Chlorhexidine-alcohol
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified November 2011 - Condition: Pituitary Macroadenoma
Intervention: Radiation: Iodine Implants
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified October 2011 - Condition: Bacterial, Viral and Other Infectious Agents
Intervention: Other: Removal of triclosan-containing cleaning products from household.
Sponsors: Stanford University; Stanford University
Recruiting - verified September 2011 - Condition: Surgical Site Infections
Interventions: Other: 2% Chlorhexidine Gluconate cloths; Other: Standard of Care preoperative preparation.
Sponsors: University of Rochester; University of Rochester; Sage Products, Inc.
Recruiting - verified December 2011 - Conditions: Tuberculosis; HIV Infections
Interventions: Drug: Rifapentine (RPT); Drug: Isoniazid (INH); Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Conditions: Recurrent Thyroid Cancer; Stage IVA Follicular Thyroid Cancer; Stage IVA Papillary Thyroid Cancer; Stage IVB Follicular Thyroid Cancer; Stage IVB Papillary Thyroid Cancer; Stage IVC Follicular Thyroid Cancer; Stage IVC Papillary Thyroid Cancer
Interventions: Drug: pazopanib hydrochloride; Radiation: iodine I 131
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI); National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Alcohol Abuse
Intervention: Behavioral: Group Brief Alcohol Intervention
Sponsors: University of Tennessee; University of Tennessee; National Cancer Institute (NCI); University of Minnesota - Clinical and Translational Science Institute; United States Air Force
Recruiting - verified July 2011 - Condition: Kidney Cancer
Interventions: Drug: Pazopanib; Drug: Temsirolimus; Behavioral: Quality of Life Assessment; Drug: Benadryl
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Not yet recruiting - verified March 2012 - Conditions: GERD; Barrett's Esophagus
Interventions: Drug: Fluorescein; Drug: Proflavine hemisulfate
Sponsors: Anandasabapathy, Sharmila, M.D.; Anandasabapathy, Sharmila, M.D.
Recruiting - verified June 2011 - Conditions: Barrett's Esophagus; Intraepithelial Neoplasia
Intervention: Drug: proflavine
Sponsors: Anandasabapathy, Sharmila, M.D.; Anandasabapathy, Sharmila, M.D.; William Marsh Rice University
Recruiting - verified September 2011 - Condition: Squamous Cell Cancer
Intervention: Drug: proflavine
Sponsors: Anandasabapathy, Sharmila, M.D.; Anandasabapathy, Sharmila, M.D.; William Marsh Rice University
Recruiting - verified June 2011 - Conditions: Colon Polyps; Colonic Dysplasia; Anal Dysplasia
Intervention: Drug: Proflavine Hemisulfate
Sponsors: Anandasabapathy, Sharmila, M.D.; Anandasabapathy, Sharmila, M.D.
Recruiting - verified June 2011 - Condition: Chronic Graft Versus Host Disease
Interventions: Drug: ECP(Methoxsalen)+Corticosteroids+Cyclosporine; Drug: Corticosteroids/Cyclosporine
Sponsors: Therakos; Therakos; Parexel
Recruiting - verified March 2012 - Safety and Efficacy Study of Ethanol Locking to Prevent Central Line Infection in Premature NeonatesConditions: Infection Associated With Catheter; Bacteremia; Sepsis
Interventions: Drug: Ethanol lock; Drug: Heparinized saline
Sponsors: East Carolina University; East Carolina University
Recruiting - verified November 2010 - Conditions: Catheter Infections; Spinal Catheter (Epidural) (Subdural); Complications, Infection or Inflammation
Intervention: Device: Chlorhexidine impregnated patch (Biopatch)
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified August 2011 - Conditions: Alcohol Consumption; Unsafe Sex
Interventions: Behavioral: Brief Motivational Intervention (BMI); Behavioral: Brief Advice
Sponsors: Brown University; Brown University; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Memorial Hospital of Rhode Island; Kent Hospital
Recruiting - verified November 2011 - Conditions: Cystic Fibrosis; Methicillin-resistant Staphylococcus Aureus
Interventions: Drug: Rifampin; Drug: Trimethoprim/Sulfamethoxazole; Drug: Minocycline; Drug: Mupirocin; Drug: chlorhexidine gluconate oral rinse; Drug: 2% Chlorhexidine solution wipes; Behavioral: Environmental Decontamination
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; CF Therapeutics Development Network Coordinating Center; Seattle Children's Hospital; University of Washington; University of Colorado, Denver; Texas Children's Hospital; University of Alabama at Birmingham; St. Louis Children's Hospital; Cook Children's Medical Center; University of Michigan Health System
Recruiting - verified January 2012 - Condition: Lung Cancer
Interventions: Procedure: therapeutic conventional surgery; Radiation: iodine I 125; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Hazardous Drinking; HIV
Intervention: Behavioral: Brief alcohol intervention
Sponsors: Brown University; Brown University
Recruiting - verified October 2011 - Condition: Acute Kidney Injury
Interventions: Drug: ATG; Drug: Rituximab; Drug: Methylprednisolone; Drug: Diphenhydramine; Drug: Acetaminophen; Drug: Tacrolimus; Drug: Sirolimus; Drug: Hydrocortisone; Drug: Prednisone
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network (ITN)
Recruiting - verified August 2011 - Conditions: Histologically or Cytologically Confirmed Pancreatic Ca; Unresectable or Borderline Resectable Pancreatic Ca
Interventions: Drug: Gemcitabine; Procedure: Intra Arterial Catheterization and Embolization; Device: Indwelling Intraarterial Catheter
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Alcohol or Other Drugs Effects
Interventions: Drug: Alcohol + Caffeine Beverage; Drug: Alcohol + Caffeine-placebo
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified January 2011 - Conditions: Nonmalignant Breast Conditions; Breast Cancer
Interventions: Device: sodium hypochlorite (Dakins Soln); Drug: Chlorhexidine gluconate disk
Sponsors: Mayo Clinic; Mayo Clinic; University of California, San Francisco
Recruiting - verified April 2012 - Conditions: Bladder Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer; Lung Cancer; Pancreatic Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Head and Neck Cancer
Interventions: Drug: Proflavine; Procedure: Imaging; Device: Widefield Multispectral Imaging Devices; Device: High-Resolution Microendoscope (HRME)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Recruiting - verified May 2012 - Conditions: Corneal Toxicity; Ototoxicity; Surgical Site Infection
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified July 2011 - Conditions: Bacterial Vaginosis; Trichomoniasis; Candidiasis
Interventions: Drug: Placebo; Drug: Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: Sinus Disease
Intervention: Drug: Bacitracin
Sponsors: Steward St. Elizabeth's Medical Center of Boston, Inc.; Steward St. Elizabeth's Medical Center of Boston, Inc.
Recruiting - verified July 2011 - Condition: Abscess
Intervention: Device: Irrisept
Sponsors: University of Florida; University of Florida; Irrimax Corporation
Recruiting - verified March 2012 - Condition: Essential Tremor
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified June 2011 - Conditions: Arthroplasty, Knee Replacement; Replacement, Total Knee; Total Knee Replacement
Interventions: Drug: Swab area with Betadine; Drug: Swab area with ChloraPrep
Sponsors: Central DuPage Hospital; Central DuPage Hospital
Recruiting - verified February 2012 - Conditions: Risk Reduction Behavior; Health Behavior; Sexual Behavior; Adolescent Behavior; Cannabis
Interventions: Behavioral: INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY); Behavioral: SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH); Behavioral: SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION
Sponsors: University of New Mexico; University of New Mexico; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified August 2011 - Conditions: Alcohol Withdrawal Delirium; Alcohol Withdrawal Associated Autonomic Hyperactivity; Alcohol Withdrawal Hallucinosis; Alcohol Withdrawal-Induced Delirium Tremens
Interventions: Drug: Dexmedetomidine; Drug: Placebo
Sponsors: Denver Health and Hospital Authority; Denver Health and Hospital Authority
Recruiting - verified April 2012 - Conditions: Hazardous Alcohol Use; Binge Drinking; High Risk Sexual Behaviors; HIV Risk Reduction; HIV Infection
Interventions: Behavioral: Computerized brief alcohol intervention with IVR booster calls; Behavioral: Computer delivered brief alcohol intervention; Behavioral: Attention Control
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Not yet recruiting - verified June 2011 - Conditions: Staphylococcus Aureus; Community-associated MRSA Infections; Staphylococcal Skin Infections
Interventions: Drug: Chlorhexidine gluconate; Other: Standardized training and education
Sponsors: Uniformed Services University of the Health Sciences; Uniformed Services University of the Health Sciences; Centers for Disease Control and Prevention
Recruiting - verified July 2011 - Conditions: Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment
Interventions: Drug: Vancomycin; Drug: Vancomycin; Drug: Daptomycin 7-14 days moderate renal impairment; Drug: Daptomycin 7 - 14 days severe renal impairment, hemodialysis; Drug: Daptomycin 7 - 14 days severe renal impairment no hemodialysis; Drug: Daptomycin 14 - 42 days, moderate renal impairment; Drug: Daptomycin 14 - 42 days, severe renal impairment on hemodialysis; Drug: Daptomycin 14 - 42 days severe renal impairment, no hemodialysis
Sponsors: Cubist Pharmaceuticals; Cubist Pharmaceuticals
Recruiting - verified September 2011 - Conditions: Neoplasms, Cystic, Mucinous, and Serous; Pancreatic Neoplasms; Ultrasonography, Interventional
Intervention: Procedure: EUS and/or ERCP with ethanol injections of pancreatic cyst
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified July 2011 - Condition: Alcohol Misuse
Interventions: Behavioral: Computer-delivered Brief Intervention (CBI); Behavioral: Intervener-delivered Brief Intervention (IBI); Behavioral: Adapted Motivational Enhancement Therapy (AMET)
Sponsors: University of Michigan; University of Michigan; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified December 2010 - Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2011 - Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Alcohol Reactivity
Interventions: Drug: varenicline; Drug: placebo
Sponsors: Yale University; Yale University
Recruiting - verified January 2012 - Conditions: At-risk Drinking; Type 2 Diabetes
Interventions: Behavioral: Brief alcohol intervention; Behavioral: General health education
Sponsors: Rhode Island Hospital; Rhode Island Hospital
Recruiting - verified July 2009 - Conditions: Alcohol-related Disorders; Post-traumatic Stress Disorder
Interventions: Behavioral: Seeking Safety; Behavioral: Couple-Based Treatment for Alcohol Use Disorders and PTSD
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified March 2012 - Conditions: Graves Disease; Hyperthyroidism
Intervention: Drug: Potassium Iodine
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester
Recruiting - verified October 2011 - Condition: Thyroid Cancer
Intervention: Radiation: Radioactive Iodine 124
Sponsors: Washington Hospital Center; Washington Hospital Center; Genzyme; IBA
Recruiting - verified August 2011 - Conditions: Alcoholism; Alcohol Dependence; Post-Tramatic Stress Disorder; fMRI
Intervention: Drug: Aprepitant
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified December 2011 - Condition: Pulp Necrosis
Interventions: Drug: Triple Antibiotic Paste; Drug: Triple Antibiotic Paste; Drug: Triple Antibiotic Paste
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio
Recruiting - verified March 2012 - Condition: Pulp Necrosis
Interventions: Drug: Double Antibiotic Paste; Drug: Triple Antibiotic Paste; Drug: Mineral Trioxide Aggregate
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio
Recruiting - verified March 2012 - Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Alcohol; Drug: Alcohol placebo
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012 - Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Radiation: iodine I 131 monoclonal antibody BC8; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Tobacco Use Cessation; Alcohol-related Disorders
Intervention: Behavioral: behavioral counseling plus contingency management
Sponsors: Yale University; Yale University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified January 2012 - Conditions: Alcohol Dependence; Depression
Interventions: Behavioral: Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD); Behavioral: Treatment as Usual
Sponsors: University of Rochester; University of Rochester; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified February 2012 - Condition: Nicotine Dependence
Intervention: Behavioral: Tobacco Research and Intervention Program
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Institutes of Health (NIH)
Recruiting - verified January 2012 - Condition: Prostate Cancer
Interventions: Biological: Ad5-CMV-NIS; Drug: liothyronine sodium; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Radiation: iodine I 131
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Pancreatic Cancer
Intervention: Radiation: Proton Therapy, Capecitabine, Gemcitabine
Sponsors: University of Florida; University of Florida
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Drug: hydroxychloroquine
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Burns
Intervention: Drug: Sulfamylon® (mafenide acetate) For 5 % Topical Solution
Sponsors: Mylan Bertek Pharmaceuticals; Mylan Bertek Pharmaceuticals; Mylan Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Radiation: total-body irradiation; Radiation: iodine I 131 monoclonal antibody BC8; Procedure: allogeneic bone marrow transplantation; Drug: tacrolimus; Drug: mycophenolate mofetil; Other: laboratory biomarker analysis; Other: flow cytometry; Genetic: cytogenetic analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Alcohol Drinking
Interventions: Drug: varenicline; Drug: bupropion; Drug: placebo
Sponsors: Yale University; Yale University
Recruiting - verified January 2012 - Conditions: B-cell Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia
Interventions: Radiation: tositumomab and iodine I 131 tositumomab; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Melanoma
Interventions: Biological: Dendritic Cell Immunization; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: T Cells; Biological: Interleukin-2
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Chiron Corporation
Recruiting - verified March 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Radiation: iodine I 131 monoclonal antibody BC8; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Childhood Langerhans Cell Histiocytosis; Fanconi Anemia; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: melphalan; Drug: methylprednisolone; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Milton S. Hershey Medical Center
Recruiting - verified October 2008 - Condition: Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified September 2011 - Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
 |
Anti Infective Agents Local Clinical Trials |
